Ning Zheng

The paper identifies single amino acid mutations that create functional degrons in transcription factors, enabling targeted protein degradation and revealing a new mechanism for disease-related protein turnover.

This study identifies DeSI1 as a cyclin D-CDK4/6 substrate whose phosphorylation regulates membrane and mitochondrial protein supply during proliferation.

This study shows that scaffold binding affinity determines condensate phase behavior, dynamics, and biochemical output in vitro and in human cells.

The paper integrates multiple affinity purification strategies to uncover novel protein interactions, validating the FOXA1-PBX1 complex as a regulatory node in estrogen receptor transcription.

This paper shows that an orthosteric inhibitor of the COP9 signalosome achieves high potency through a molecular glue mechanism that enhances substrate-dependent binding.

The paper identifies PCMT1 as an enzyme that forms C-terminal cyclic imides on CRBN substrates, linking it to metabolic enzyme regulation and epileptic phenotypes.

This study identifies UBR-1 as a hub regulating glutamate homeostasis through a signaling axis, affecting locomotion and developmental viability in C. elegans.

This paper identifies UM171 as a molecular glue that promotes degradation of HDAC1/2 complexes by inducing asymmetric interactions between KBTBD4 and HDAC1.

This study identifies how KBTBD4 cancer mutations drive neomorphic interactions with HDAC1/2, leading to CoREST degradation and tumor growth, and shows potential therapeutic strategies.

This study reveals how two F-box proteins, FBXO22 and FBXL17, recognize distinct structural features of the BACH1 BTB dimer under oxidative stress, leading to its ubiquitination and degradation.

The paper develops RosettaVS, an AI-accelerated virtual screening platform that identifies drug candidates with high binding affinity across two targets, achieving a 14% and 44% hit rate in under seven days.